Literature DB >> 17389525

The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation.

Sudipto Mukherjee1, Clyde Guidry.   

Abstract

PURPOSE: The goal of this study was to determine the influence, if any, of the insulin-like growth factors (IGFs) on retinal pigment epithelial (RPE) cell tractional force generation and the contributions of vitreous insulin-like growth factor-binding proteins (IGFBPs) toward control of growth factor activity.
METHODS: IGF effects on RPE were evaluated in tissue culture assays that involved incubation on three-dimensional collagen matrices with responses measured as progressive reduction in matrix thickness. IGFBP effects were evaluated by using the same system, exposing cells to a non-IGFBP-binding growth factor analogue (R(3)IGF-I) or IGFBPs alone or in combination with native growth factors.
RESULTS: RPE cells generated tractional forces in response to IGF-I and -II with IGF-I being the more potent stimulus. Differential RPE responses to R(3)IGF-I reflected minor amounts of endogenous IGFBP production. IGFBP-2, -3, and -5 were effective inhibitors of both ligands, whereas IGFBP-6 reduced cell responses to IGF-II only. IGFBP-direct effects on the cells were binding-protein-specific, in that IGFBP-1 had detectable stimulatory effects, and IGFBP-3, -4, -5, and -6 inhibited RPE responses.
CONCLUSIONS: IGF-I and -II are potent promoters of RPE cell tractional force generation in vitro. The effects of the six high-affinity IGFBPs on RPE responses are generally inhibitory and protein-specific. IGF ligands and binding proteins are known to be present in the vitreous, the environment that drives RPE responses in proliferative vitreoretinopathy (PVR), suggesting that the IGF system plays a potentially important role in the pathophysiology of this fibrocontractive disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17389525     DOI: 10.1167/iovs.06-1095

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  19 in total

1.  Free insulin-like growth factor binding protein-3 (IGFBP-3) reduces retinal vascular permeability in association with a reduction of acid sphingomyelinase (ASMase).

Authors:  Jennifer L Kielczewski; Sergio Li Calzi; Lynn C Shaw; Jun Cai; Xiaoping Qi; Qing Ruan; Lin Wu; Li Liu; Ping Hu; Tailoi Chan-Ling; Robert N Mames; Sue Firth; Robert C Baxter; Patric Turowski; Julia V Busik; Michael E Boulton; Maria B Grant
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-21       Impact factor: 4.799

2.  Anti-EMP2 diabody blocks epithelial membrane protein 2 (EMP2) and FAK mediated collagen gel contraction in ARPE-19 cells.

Authors:  Shawn A Morales; David G Telander; Sergey Mareninov; Agnes Nagy; Madhuri Wadehra; Jonathan Braun; Lynn K Gordon
Journal:  Exp Eye Res       Date:  2012-06-19       Impact factor: 3.467

3.  Growth factors outside the PDGF family drive experimental PVR.

Authors:  Hetian Lei; Gisela Velez; Peter Hovland; Tatsuo Hirose; Debra Gilbertson; Andrius Kazlauskas
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-25       Impact factor: 4.799

4.  The Project MACULA Retinal Pigment Epithelium Grading System for Histology and Optical Coherence Tomography in Age-Related Macular Degeneration.

Authors:  Emma C Zanzottera; Jeffrey D Messinger; Thomas Ach; R Theodore Smith; K Bailey Freund; Christine A Curcio
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-05       Impact factor: 4.799

5.  Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses.

Authors:  Steven Pennock; Andrius Kazlauskas
Journal:  Mol Cell Biol       Date:  2012-03-19       Impact factor: 4.272

Review 6.  Proliferative Vitreoretinopathy: A Review.

Authors:  Sana Idrees; Jayanth Sridhar; Ajay E Kuriyan
Journal:  Int Ophthalmol Clin       Date:  2019

7.  A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy.

Authors:  Steven Pennock; Marc-Andre Rheaume; Shizuo Mukai; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2011-10-28       Impact factor: 4.307

8.  Connective tissue growth factor as a mediator of intraocular fibrosis.

Authors:  Shikun He; Youxin Chen; Rima Khankan; Ernesto Barron; Richard Burton; Danhong Zhu; Stephen J Ryan; Noelynn Oliver; David R Hinton
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-30       Impact factor: 4.799

9.  Activation of the IGF1 pathway mediates changes in cellular contractility and motility in single-suture craniosynostosis.

Authors:  Zeinab Al-Rekabi; Marsha M Wheeler; Andrea Leonard; Adriane M Fura; Ilsa Juhlin; Christopher Frazar; Joshua D Smith; Sarah S Park; Jennifer A Gustafson; Christine M Clarke; Michael L Cunningham; Nathan J Sniadecki
Journal:  J Cell Sci       Date:  2015-12-11       Impact factor: 5.285

Review 10.  Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy.

Authors:  Hetian Lei; Marc-Andre Rheaume; Andrius Kazlauskas
Journal:  Exp Eye Res       Date:  2009-11-25       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.